Aims:
This retrospective, chart review of prospectively collected data evaluates the clinical outcomes of patients who were treated with MUSE for GERD in a single center.
Methods:
All patient who underwent MUSE at our endoscopy center between May 2015 and June 2018 were retrospectively identified from a prospective database, collected and analyzed. The procedure was offered to patients with GERD who required and responded to pharmacological therapy. Symptoms were evaluated with a validated clinical score – GERD-HRQL score – and by monitoring the use and dosage of PPI. Clinical success was defined by ≥50% reduction of the dosage of PPI and by the GERD HRQL score (≥50% reduction compared to baseline or normalization [< 10] of the score).
Results:
Tab. 1:
Results
|
patients (19)
|
Baseline 19 patients with f/u
|
Last follow-up (mean 14 months) 19 patient
|
p
|
|
PPI usage
|
100%
|
32%
|
< 0.0001
|
|
median GERD-HQRL (SD)
|
30.3 (± 7.5)
|
16.3 (± 11.2)
|
< 0.0001
|
|
median % TRT (SD)
|
14.7% (± 9.81)
|
6.24% (± 7.05)
|
< 0.05
|
|
median DeMeester Score (SD)
|
50.17 (± 40.49)
|
30.34 (± 42.6)
|
0.17
|
A total of 25 patients underwent MUSE during the study period (mean age 52 [± 13], 64% males). Five patients did not complete the minimum 6-month follow-up and were excluded from analysis. One patient was lost to follow-up immediately after treatment. A median follow-up of 13.9 (6 – 36) months was available for 19 patients. At the date of the last visit, clinical success was achieved in 69% of patients (11 patients discontinued PPI and 2 patients take < 50% of the initial dosage). GERD-HRQL score was normalized or improved by ≥50% compared to baseline in 11 patients (58%). % TRT score was normal in 10/15 patients (66.6%) with post-operative pH-monitoring study.
Conclusions:
Our study confirms the safety and efficacy of the MUSE procedure for the treatment of GERD.
